PF-06795071

• Description:

  PF-06795071 is a potent and selective covalent MAGL inhibitor with an IC50 of 3 nM[1].

• UNSPSC:

  12352005

• Target:

  MAGL

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/PF-06795071.html

• Purity:

  99.31

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  OC[C@H](C(F)(F)F)OC(N1C[C@]([C@@]2([H])C1)([H])[C@H]2C3=NN(C4=CC=C(F)C=C4)C=C3)=O

• Molecular Formula:

  C18H17F4N3O3

• Molecular Weight:

  399.34

• References & Citations:

  [1]McAllister LA, et al. Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation. J Med Chem. 2018 Apr 12;61 (7) :3008-3026.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2075629-81-9]